MEI Pharma Investor Relations Material
Latest events
Q4 2023
MEI Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from MEI Pharma Inc
Access all reports
MEI Pharma Inc, formerly known as Marshall Edwards Inc., is a clinical-stage pharmaceutical company focusing on developing innovative therapies for cancer treatment. The company's drug development focus includes pracinostat, an oral histone deacetylase inhibitor aimed at treating advanced hematological diseases such as myelodysplastic syndrome. Additionally, MEI Pharma is working on ME-344, a mitochondrial inhibitor for the treatment of HER2-negative breast cancer and solid tumors, and Zandelisib (ME-401), an oral PI3K delta inhibitor for relapsed or refractory B-cell malignancies. Another key drug candidate is Voruciclib, an oral and selective cyclin-dependent kinase (CDK) inhibitor intended for the treatment of acute myeloid leukemia (AML) and B-cell malignancies, being developed in agreement with Presage. It is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Latest articles
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Anthony Noto: The Multifaceted CEO of SoFi
Anthony Noto built a successful and diverse career across multiple industries before becoming CEO of the fintech company SoFi.
9 Dec 2024
Ticker symbol
MEIP
Country
🇺🇸 United States